Yuhei Chiba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yuhei Chiba has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Omi Katsuse
Department of Psychiatry, Yokohama City University Graduate School of Medicine 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan; Yokohama Hoyu Hospital 644 Kanegaya, Asahi-ku, Yokohama, 241-0812, Japan
8 shared publicationsAkira Suda
Department of Psychiatry, Yokohama City University Graduate School of Medicine 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan
5 shared publications- Kie Abe
Yokohama City University Graduate shool of medicine, Department of Psychiatry, Yokohama, Kanagawa, Japan
5 shared publications Yoshio Hirayasu
Department of Psychiatry Yokohama City University School of Medicine Yokohama Japan
5 shared publications- Akitoyo Hishimoto
Kobe University graduate school of medicine, department of Psychiatry, Kobe, Hyogo, Japan
4 shared publications Asuka Yoshimi
Department of Psychiatry, Yokohama City University School of Medicine, Kanazawa-ku, Yokohama, Japan
4 shared publications
Latest Publications
- Open Access
- 22 May 2026
- Published by Elsevier in Archives of Gerontology and Geriatrics Plus
- Vol. 3  (3)
Association between activity levels and sleep in Community-Dwelling older adults: Insights from a dementia prevention trial using wearable devices
- 22 May 2026
- Published by Elsevier in Archives of Gerontology and Geriatrics Plus
- Vol. 3  (3)
Open AccessAssociation between activity levels and sleep in Community-Dwelling older adults: Insights from a dementia prevention trial using wearable devices
- 5 May 2026
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 149, 106289
Multimodal intervention benefits: Responder analysis of J-MINT PRIME Kanagawa trial
- 5 May 2026
- Published by Elsevier in Archives of Gerontology and Geriatrics
- Vol. 149, 106289
Multimodal intervention benefits: Responder analysis of J-MINT PRIME Kanagawa trial
- 1 July 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106  (2) , 574-588
Japan-multimodal intervention trial for the prevention of dementia in older people with lifestyle-related diseases: A community-based, 18-month, randomized controlled trial
Background: The prevalence of Alzheimer's disease is increasing in Japan, highlighting the need to establish evidence-based strategies for its prevention. Objective: We aimed to evaluate the effectiveness of a multimodal community-based intervention for Japanese older people with lifestyle-related diseases and to identify challenges in implementing such interventions to prevent dementia in local communities. Methods: An 18-month randomized controlled trial was conducted among individuals aged 65–85 years with lifestyle-related diseases (hypertension, hyperlipidemia, diabetes, overweight/underweight, smoking), residing in a single apartment complex. Participants were randomly assigned to a multimodal intervention group (group-based physical exercise, nutritional guidance, management of lifestyle-related diseases, and cognitive training) or a control group. The primary outcome was the change in the composite score derived from seven neuropsychological tests. The trial was registered (UMIN000041887: September 24, 2020). Results: Of 224 screened individuals, 198 were randomized (99 in each group), and 175 (88.4%) completed the 18-month assessment. There was no significant difference between the intervention and control groups in the primary outcome (change in composite test score: 0.25; 95% confidence interval 0.16 to 0.33 versus 0.29; 95% confidence interval 0.20 to 0.38, respectively; p = 0.463). However, a subgroup analysis of participants with mild cognitive impairment showed a significant intervention effect on changes in logical memory, for both immediate ( p = 0.041) and delayed recall tasks ( p = 0.043). Conclusions: This multimodal intervention program demonstrated no effectiveness in mitigating cognitive decline. Further research is needed to develop more effective strategies and to better define target populations.
- 1 July 2025
- Published by SAGE Publications in Journal of Alzheimer’s Disease
- Vol. 106  (2) , 574-588
Japan-multimodal intervention trial for the prevention of dementia in older people with lifestyle-related diseases: A community-based, 18-month, randomized controlled trial
Background: The prevalence of Alzheimer's disease is increasing in Japan, highlighting the need to establish evidence-based strategies for its prevention. Objective: We aimed to evaluate the effectiveness of a multimodal community-based intervention for Japanese older people with lifestyle-related diseases and to identify challenges in implementing such interventions to prevent dementia in local communities. Methods: An 18-month randomized controlled trial was conducted among individuals aged 65–85 years with lifestyle-related diseases (hypertension, hyperlipidemia, diabetes, overweight/underweight, smoking), residing in a single apartment complex. Participants were randomly assigned to a multimodal intervention group (group-based physical exercise, nutritional guidance, management of lifestyle-related diseases, and cognitive training) or a control group. The primary outcome was the change in the composite score derived from seven neuropsychological tests. The trial was registered (UMIN000041887: September 24, 2020). Results: Of 224 screened individuals, 198 were randomized (99 in each group), and 175 (88.4%) completed the 18-month assessment. There was no significant difference between the intervention and control groups in the primary outcome (change in composite test score: 0.25; 95% confidence interval 0.16 to 0.33 versus 0.29; 95% confidence interval 0.20 to 0.38, respectively; p = 0.463). However, a subgroup analysis of participants with mild cognitive impairment showed a significant intervention effect on changes in logical memory, for both immediate ( p = 0.041) and delayed recall tasks ( p = 0.043). Conclusions: This multimodal intervention program demonstrated no effectiveness in mitigating cognitive decline. Further research is needed to develop more effective strategies and to better define target populations.
- 15 May 2024
- Published by Taylor & Francis in Assistive Technology
- Vol. 36  (6) , 398-404
Wheelchair dependence in patients with dementia: Focus on kinematic gait analysis using simple wearable accelerometers and gyroscopes
Falls, wheelchair dependence, and bedridden status are the results of reduced mobility in the mid-late course of dementia. Kinematic gait analysis for patients with dementia is lacking because practically setting sensors on their bodies is particularly difficult. We analyzed the parameters of kinematic gait analysis that are related to the risks of wheelchair dependence in patients with dementia using wearable accelerometers and gyroscopes for detecting 3-dimensional physical movements. We collected data from 34 patients with dementia regarding demographics, cognitive function, CT scan findings, medications, and gait analysis parameters. The patients were followed up for 6 months. We compared data between dementia patients with and without wheelchair dependence by t-test or Fisher's exact test, multiple comparison, and simple logistic regression analysis for wheelchair dependence by gait analysis parameters. Eleven patients became wheelchair-dependent during the 6 months. The score on the clinical dementia rating scale was significantly higher and the hip extensor angle in walking was significantly lower in patients with dementia with wheelchair dependence than in those without. The severity of dementia and the lower angle of the hip extensor during walking may indicate the necessity of a wheelchair for patients with this disease.
- 15 May 2024
- Published by Taylor & Francis in Assistive Technology
- Vol. 36  (6) , 398-404
Wheelchair dependence in patients with dementia: Focus on kinematic gait analysis using simple wearable accelerometers and gyroscopes
Falls, wheelchair dependence, and bedridden status are the results of reduced mobility in the mid-late course of dementia. Kinematic gait analysis for patients with dementia is lacking because practically setting sensors on their bodies is particularly difficult. We analyzed the parameters of kinematic gait analysis that are related to the risks of wheelchair dependence in patients with dementia using wearable accelerometers and gyroscopes for detecting 3-dimensional physical movements. We collected data from 34 patients with dementia regarding demographics, cognitive function, CT scan findings, medications, and gait analysis parameters. The patients were followed up for 6 months. We compared data between dementia patients with and without wheelchair dependence by t-test or Fisher's exact test, multiple comparison, and simple logistic regression analysis for wheelchair dependence by gait analysis parameters. Eleven patients became wheelchair-dependent during the 6 months. The score on the clinical dementia rating scale was significantly higher and the hip extensor angle in walking was significantly lower in patients with dementia with wheelchair dependence than in those without. The severity of dementia and the lower angle of the hip extensor during walking may indicate the necessity of a wheelchair for patients with this disease.
- Open Access
- 21 January 2022
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 9  (2) , 331-337
Plasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer's Disease Neuroimaging Initiative Database
Matrix metalloproteinase 9 (MMP-9) has been reported to be correlated with declines in hippocampal volume and cognitive function in ApoE4-positive MCI pati
- 21 January 2022
- Published by Elsevier in The Journal Of Prevention of Alzheimer's Disease
- Vol. 9  (2) , 331-337
Open AccessPlasma MMP-9 Levels as the Future Risk of Conversion to Dementia in ApoE4-Positive MCI Patients: Investigation Based on the Alzheimer's Disease Neuroimaging Initiative Database
Matrix metalloproteinase 9 (MMP-9) has been reported to be correlated with declines in hippocampal volume and cognitive function in ApoE4-positive MCI pati
- 20 September 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 430, 119997
Genetic and demographic predisposing factors associated with pediatric sleepwalking in the Philadelphia Neurodevelopmental Cohort
- 20 September 2021
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 430, 119997
Genetic and demographic predisposing factors associated with pediatric sleepwalking in the Philadelphia Neurodevelopmental Cohort
- Open Access
- 28 June 2021
- Published by Korean Epilepsy Society in Journal of Epilepsy Research
- Vol. 11  (1) , 93-95
A Severe Dementia Case in End of Life Care with Psychiatric Symptoms Treated by Perampanel
Epilepsy is known to comorbid with Alzheimer's disease. It can promote cognitive decline, and eventually worsen their prognosis and mortality. It is sometimes difficult to find a suitable drug because of the adverse effects. Perampanel has a unique mechanism of action that antagonizes α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid type glutamate receptor. Here, we report a case of severe dementia due to Alzheimer's disease with intractable epilepsy, which perampanel effected for controlling seizures with less adverse effects. The subject is an 89-year-old Japanese woman with severe dementia due to Alzheimer's disease and intractable myoclonic epilepsy. She also had psychiatric symptoms, such as circadian rhythm disorder and irritability. Valproic acid, lacosamide, or carbamazepine were prescribed, but none of them was effective. Shortly after perampanel started, however, myoclonus and these psychiatric symptoms improved. Moreover, it did not cause any obvious adverse effects, which made it possible to continue perampanel until the end of her life. Perampanel may be useful for controlling intractable epilepsy accompanied by Alzheimer's disease. It may also improve psychiatric symptoms with less adverse effect. Accumulation of studies is necessary to evaluate the effectiveness of perampanel on the epilepsy of Alzheimer's disease patients and further understand that mechanism.
- 28 June 2021
- Published by Korean Epilepsy Society in Journal of Epilepsy Research
- Vol. 11  (1) , 93-95
Open AccessA Severe Dementia Case in End of Life Care with Psychiatric Symptoms Treated by Perampanel
Epilepsy is known to comorbid with Alzheimer's disease. It can promote cognitive decline, and eventually worsen their prognosis and mortality. It is sometimes difficult to find a suitable drug because of the adverse effects. Perampanel has a unique mechanism of action that antagonizes α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid type glutamate receptor. Here, we report a case of severe dementia due to Alzheimer's disease with intractable epilepsy, which perampanel effected for controlling seizures with less adverse effects. The subject is an 89-year-old Japanese woman with severe dementia due to Alzheimer's disease and intractable myoclonic epilepsy. She also had psychiatric symptoms, such as circadian rhythm disorder and irritability. Valproic acid, lacosamide, or carbamazepine were prescribed, but none of them was effective. Shortly after perampanel started, however, myoclonus and these psychiatric symptoms improved. Moreover, it did not cause any obvious adverse effects, which made it possible to continue perampanel until the end of her life. Perampanel may be useful for controlling intractable epilepsy accompanied by Alzheimer's disease. It may also improve psychiatric symptoms with less adverse effect. Accumulation of studies is necessary to evaluate the effectiveness of perampanel on the epilepsy of Alzheimer's disease patients and further understand that mechanism.
- 1 January 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 743, 135588
Exploratory investigation on antibodies to GluN1 and cognitive dysfunction in patients with chronic autoimmune psychosis
- 1 January 2021
- Published by Elsevier in Neuroscience Letters
- Vol. 743, 135588
Exploratory investigation on antibodies to GluN1 and cognitive dysfunction in patients with chronic autoimmune psychosis
- 1 September 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 416, 116989
Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database
- 1 September 2020
- Published by Elsevier in Journal of the Neurological Sciences
- Vol. 416, 116989
Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database